Form 8-K - Current report:
SEC Accession No. 0001213900-21-052090
Filing Date
2021-10-08
Accepted
2021-10-08 17:02:30
Documents
13
Period of Report
2021-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea148616-8k_abvcbiophar.htm   iXBRL 8-K 34231
2 JOINT VENTURE AGREEMENT BETWEEN THE COMPANY, LUCIDAIM CO., LTD. AND BIOLITE JAPA ea148616ex10-1_abvcbiopharma.htm EX-10.1 346106
  Complete submission text file 0001213900-21-052090.txt   603561

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE abvc-20211008_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE abvc-20211008_pre.xml EX-101.PRE 22363
5 XBRL SCHEMA FILE abvc-20211008.xsd EX-101.SCH 3031
6 EXTRACTED XBRL INSTANCE DOCUMENT ea148616-8k_abvcbiophar_htm.xml XML 3172
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 211315933
SIC: 2834 Pharmaceutical Preparations